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ABSTRACT
According to the Centers for Disease Control and Prevention, stroke is
statistically responsible for 1 in every 19 deaths of American citizens.5 Stroke is the
leading cause of permanent disability due to the fact that it compromises both cellular
and tissue components of the brain, leading to the formation of a physical void within the
tissue.
Current research approaches address the cellular component by injecting stem
cells into this void; however, extremely low cell engraftment, high injected cell death, and
overall no matrix regeneration are observed. Additionally, these stem cells do not remain
committed to a neural lineage. We propose to overcome these obstacles by
incorporating a tissue engineered niche matrix component to the delivery of such stem
cells. We hypothesize the implantation of this construct will lead to brain regeneration
with complete sensory and motor functional recovery.
Niche neural constructs were successfully created and characterized in vitro. In
addition to maintaining and supporting the life of induced neural-like cells, seeding
HADSCs onto these scaffolds yielded spontaneous differentiation and overall extended
cell viability.
After implantation into MCAO stroke-afflicted rats for 4 weeks, rats treated with
niche neural constructs showed significant recovery when compared to stroked controls
(P<0.05) as early as 2 weeks post-stroke culminating in 98% recovery. Histological
evidence showed integration of the construct with host tissue, an absence of reactive
astrocytes,

widespread

neovascularization,

ii

and

significant

tissue

remodeling.

Additionally after 4 weeks the implanted cells were still committed to a neuron lineage
and have remained engrafted to the construct area. Additionally, numerous non-human
neurons were observed within the construct area, further indicating integration with host
tissue and overall, validating this approach towards functional brain tissue regeneration.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1 Neural Anatomy and Physiology
The brain is divided into two almost completely symmetric hemispheres.
Additionally, the brain can be divided into four lobes. Each lobe controls different bodily
functions, but a complete map of the brain shows that different functions are associated
with specific anatomical structures. These structures differ in their comprising matrix as
well as the number and types of neural cells observed.
1.1.1. Matrix
Brain matrix can be divided into two categories, grey and white matter. Grey
matter contains cell bodies, glial  cells,  and  vessels.  It  is  termed  “grey”  due  to  the  lack  of  
myelinated axons, which are characteristically white in color. White matter, then, is
primarily composed of these myelinated axons as well as glial cells. Functionally, white
matter is associated with action potentials and thus cognition via intra brain
communication and body-brain communication. These structural differences allow for
distinct histological identification between brain regions. Most notably, white mater will
stain very heavily for myelin while grey matter will not stain. Additionally, white matter
characteristically appears fragmented compared to grey mater. This fragmentation is
largely due to the heavy lipid concentration within the matrix.
Glycosaminoglycans (GAGs) are one of the most well-characterized neural
extracellular matrix (ECM) components.1

GAGs are proteoglycans composed of a

protein core with repeated disaccharide units. The polar nature of these molecules
makes them extremely hydrophilic, functioning as a shock-absorbing material.
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Additionally, GAGs within the brain function in cell signaling, tissue morphogenesis,
neuronal cell migration, and axon regeneration.1, 2 Though GAGs are widely present in
healthy brain tissue, the up-regulation of chondroitin sulfate proteoglycans is a direct
result of glial scar formation.2 Thus any newly formed neural tissue with both a strong
GAG presence and activated astrocytes should undergo further phenotypic examination
as potential glial scarring.
Collagen and Laminin are notable fibrous components in the brain. Collagen IV is
the dominating collagen type due to its presence in the basement membrane. Overall,
fibrous components are not heavily present in the brain.1 However they serve numerous
functional roles including providing structure, directing cell differentiation and
proliferation, and aiding in development.1, 3
1.1.2. Cellular Components

Figure 1: Astrocytes, microglia, and oligodendrocytes
are all considered accessory cells to the neurons, which
are the primary neural cell and function as chemical and
electrical transport cells.
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There are four main neural cell types, three of which are categorized as
accessory cells to the neuron: astrocytes, microglia, and oligodendrocytes. Inactivated
astrocytes are known for their maintenance of the blood-brain barrier through
interactions with capillaries. The function of microglia is similar to that of leukocytes.
Oligodendrocytes are the myelin producing cells within the brain, sheathing axons with
electrical insulation. Lastly, the neuron is the chemical and electrical signaling cell
responsible for the transmission of information to and from the brain and all other parts
of the body.
1.2 Stroke
Cerebral ischemia, more commonly known as stroke, is responsible for 11.1% of all
deaths worldwide.4 According to the Centers for Disease Control and Prevention (CDC),
stroke is statistically responsible for 1 in every 19 deaths of American citizens, costing
over $38.6 billion in medical expenses.5 The most alarming statistic of stroke comes from
a 2011 study conducted by the CDC reporting that over the past 10 years, stroke
prevalence has increased 40% in those aged under 30, leaving a larger and larger
population debilitated for a longer period of time.6
1.2.1

Pathology
Just this year, the stroke council of the American Heart Association met to create

what   they   termed   a   “working   definition   of   stroke   for   the   21st century,”   and   they  
determined stroke is brain cell death resulting from oxygen deprivation.7 There are two
main ways this can occur. In hemorrhagic stroke a cerebral blood vessel leaks or bursts.
Secondly, in ischemic stroke a blood clot forms within a cerebral vessel. Ischemic stroke
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is by far the more common, but regardless of type, due to nerve tract decussation, stroke
symptoms occur contralateral to the damaged tissue.

Figure 2: There are two main types of stroke. In the first, hemorrhagic,
blood leaks into brain tissue after the bursting of a vessel. In ischemic
stroke, there is actual blood clot formation within the cerebral
vasculature.

Such clots produce both physical and functional damage. When this damage is
left untreated extensive tissue necrosis occurs, leading to the formation of a tissue void
within the neural cavity, as seen in figure 3.8 This extreme body response is largely due

Figure 3: Stroke Progression. CT images showing the progression of lesion formation within
the neural cavity. Left: the healthy brain. Middle: the brain shortly after stroke. Right: the
lesion resulting from the necrosis of stroked tissue areas.
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to the fact that the previously mentioned neural cell types, most notably the neuron,
have limited to no regenerative capacity. When a neuron becomes damaged, the neural
immune response is initiated which leads to the up-regulation of numerous cytokines
and the disabling of cell adhesion molecules causing further cell death. Moreover, these
events activate the astrocytes, initiating the cascades heralded as the inhibitors of neural
regeneration, the most pressing example being the formation of the glial scar. 9
1.2.2

Clinical Interventions
Tissue Plasminogen Activator (tPA) is the only drug approved for clinical use in

treating stroke, and even its use is extremely confined by administration restrictions.
Additionally, tPA is only effective in the treatment of ischemic stroke. As seen below in
the current clinical scenario for a stroke patient, the most pressing piece of information is
if it has been less or greater than three hours since the onset of symptoms.

Figure 4: Current clinical scenario for a stroke patient highlighting the
limitations of the only FDA approved stroke treatment, tPA, as well as
demonstrating the significance of the three hours immediately following the
onset of stroke symptoms.
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tPA can only be administered if it has been less than three hours since symptom
onset and the patient meets the drug use indications. If it has been more than three
hours and there is visible damage on a CT or MRI, clot retrieval devices can by
employed to restore blood flow. However, if it has been more than three hours and there
is no visible damage, patients are simply moved to supportive care. In all of these cases,
it is important to recognize that these clinical interventions treat the clot, not the
functional damage the clot already caused. There is a dire need for solutions that aim to
restore this physical and functional damage.
1.3 Treatment Approaches
Though tPA is the only FDA approved stroke treatment, there are promising
research initiatives in all stages of development. Most of these methods aim to restore
cell numbers to pre-ischemic levels through the administration of cells or pre-conditioned
stem cells.
1.3.1 Cellular-Focused Approaches
Cell-focused stroke therapies typically employ neural progenitor cells or nonembryonic stem cells. The traditionally hypothesized mechanism of action is that these
cells would migrate to damaged brain areas, and re-populate the area with viable cells
by differentiating into various neural cell types.
Neural Progenitor Cells (NPCs)
Utilizing NPCs is very promising, because they have been proven to differentiate
into all neural cell types.10 Though recent studies have discovered new sources of NPCs
in the adult brain, particularly in the sub-ventricular zone, these cells have limited
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differentiation potential.11 The only true source of neural progenitors is the fetal brain,
shrouding NPC use in ethical concerns.10
Stem Cells
Non-embryonic stem cells, particularly bone marrow derived stromal cells and
adipose derived stem cells do not have these ethical concerns. They have proven neural
differentiation potential, and they can be donor specific to avoid rejection via the
generation of an immune response.12 Strong arguments favoring the use of human
adipose derived stem cells (HADSCs) are the vast abundance of adipose tissue
(compared to bone marrow), more tissue can be removed per procedure generating a
higher stem cell yield, and the procedure to obtain the stem cells is far less invasive.12-15

Figure 5: Human Adipose Derived Stem Cells. Lipoaspirate is obtained from the patient, this is
enzymatically processed to obtain the stromal vascular fraction, and this fraction is plated and
cultured to obtain the adipose derived stem cells. These stem cells have numerous proven
differentiation lineages including neural applications.
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As illustrated above, removed adipose tissue can be enzymatically processed yielding a
stromal derived fraction, and this fraction can be cultured to obtain the HADSCs.
The testing of these stem cells in vivo has been widely documented. There are
two main methods of administration, intravenous and intracranial injection. In both
cases, stem cell therapies increase the treatment window from 3 hours to 7 or more
days. Moreover, the behavioral testing results indicate varying degrees of functional
recovery.16-19 However, overall there is minimal cell retention to the target tissue. One of
the most notable studies showed only a 1% retention rate to the brain.18 There are also
reports of extensive cell death, little to no decrease in the size of the lesion cavity, and
overall poor differentiation. 16-20
Evaluation of Differentiation
Unfortunately there is no one marker for neural cells, but there are a handful of
commonly used markers indicating successful differentiation. The first such marker is

A

B

C

Figure 6: Commonly used markers of neural differentiation. A) Nestin, a cytoskeletal neural progenitor marker. B)
Map-2, a cytoskeletal neuron marker. C) GFAP, a cytoskeletal astrocyte marker. Note: GFAP is regularly expressed
by astrocytes, but it is heavily up regulated post neural injury.

Nestin which is a neural progenitor marker.13-15 As figure 6A illustrates it is a cytoplasmic
marker, and it is known to be minimally expressed by HADSCs. 14 Map-2 (figure 6B) is
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also cytosolic as it is the protein responsible for the creation and maintenance of neural
cell projections.14,

15, 21

It is widely accepted in the literature that Map2 expression

indicates a cell committed to a neuron lineage. Lastly, GFAP (figure 6C) is a structural
cytoskeletal marker, and it is widely accepted that GFAP expression indicates an
astrocyte or astrocyte-like cell.14, 22
1.3.2 Conditioning-Focused Approaches
In an effort to enhance the expression of such neural markers, researchers have
begun chemically treating stem cells through a process known as neural induction.13-15,
22, 23

It is impossible to reference neural induction without mentioning Woodbury,

specifically his 2000 publication which is the foundation of all neural induction
approaches (see figure 7). 24
The medium used to induce differentiation is referred to as neural induction
medium (NIM). Neural induction protocols typically differ in the chemical base of the NIM
utilized for induction. Unfortunately, there is an inverse relationship between induced cell
viability and success of differentiation.25 Harsh chemicals yield extensive cell death with
promising differentiation potential, while less intense chemicals yield strong, relatively
undifferentiated cell populations. A balance of sustained neural differentiation and cell
viability has yet to be attained.23 As such, in vitro neural induction has a finite life calling
any in vivo or clinical efficacy of the process into question. To date, neural induction has
not been replicated in animal stroke models.10

9

Figure 7: Neural  Induction.  Woodbury’s  2000  publication  can  be  seen  as  the  gold  standard  for  neural  induction,  as  his  
neural induction medium is the chemical cocktail upon which all subsequent neural induction approaches have been
based.

1.3.3 Extracellular Matrix-Focused Approaches
Overall, there is no investigation into the incorporation of a matrix component in
the stroke-treatment field. This is surprising for a two main reasons. Firstly, as previously
described, stroke compromises neural cells and neural tissue, so an effective treatment
would need to address both of these components. Secondly, the benefits of the
incorporation of a matrix are extremely well documented.21, 26-28
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The extracellular matrix is the secretion products of resident cells. 26,

27

It is

biomolecularly tissue-specific, so any slight change in the microstructure can alter
resident cell phenotype and function. The ECM is a natural niche environment, meaning
it contains the cues for cellular migration, proliferation, and differentiation. 21,

26-28

More

notably, it has been proven to induce host tissue remodeling.26
For these reasons, extracellular matrix is incorporated into an array of
regenerative approaches including the skin, kidney, lung, as well as other neural fields in
the form of a gel.21,

29, 30

Figure 8 shows a collagen gel used in traumatic brain injury

models, and figure 9 illustrates a tissue engineered gel both loaded into the syringe and
in reconstituted form after subcutaneous implantation.

Figure 8: Scanning electron microscopy image of a
collagen gel utilized in traumatic brain injury models.

Figure 9: A tissue engineered gel loaded for delivery (left) and reconstituted (right).
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The appeal of these gels is that their delivery would be minimally invasive. 29 However,
gels are only approximations of the target tissue.21 Therefore, in traumatic brain injury
models, no real reduction in lesion cavity size and again no proven matrix regeneration
are observed.16, 30

CHAPTER 2: PROJECT APPROACH
2.1 Overview
The creation of a matrix component that more closely mimics native brain tissue
and its combination with the previously investigated cellular and induction will create a
new platform for stroke treatment. For this reason, tissue engineering is the most
appealing approach to further stroke treatment investigations.
The goal of tissue engineering is commonly described as creating functional
substitutes for damaged tissues.31 As illustrated below, the tissue engineering paradigm
usually involves harvesting target xenogeneic tissues and chemically treating them
through a process known as decellularization to obtain a matrix component, referred to
as the scaffold.26, 31-33 Simultaneously, adipose tissue is removed from the patient, and
the tissue is processed to isolate the HADSCs. These HADSCs are then cultured and
chemically treated through neural induction producing neural-like cells. These neural-like
cells can then be seeded back onto the scaffold, and this resulting construct (cells +
scaffold) can be implanted into the patient, ultimately returning living viable tissue to the
damaged areas.

12

Figure 10: The tissue engineering paradigm: Porcine brains are chemically treated to obtain a matrix
component referred to as a scaffold. Simultaneously, adipose tissue is removed from the patient and this tissue
is processed to obtain the adipose derived stem cells. These cells are chemically treated through neural
induction and seeded onto the scaffold. The resulting construct is then implanted into the stroke patient
ultimately retuning living tissue and overall function to the area.

The long-term goal for this project is the creation of a clinical alternative for
patients suffering from stroke that yields complete functional recovery. Ultimately such a
recovery involves regeneration of viable native neural tissue in areas compromised by
stroke. This regenerated tissue will not be immunogenic, will fully integrate with host
tissue, will maintain properties necessary for neural cell growth and maintenance, and
will ultimately lead to complete restoration of lost function. The hypothesis being
examined is that niche tissue-engineered scaffolds reseeded with adipose derived stem
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cells will, upon implantation, return living neural tissue and restore overall function to
area compromised by stroke.
2.2 Specific Aims
Validating the hypothesis that neural tissue regeneration and therefore functional
stroke recovery can be achieved through this tissue engineering approach requires the
successful completion of three specific aims.
2.2.1 Aim I: Create and Characterize a Tissue-Engineered Neural Scaffold
Our goal is to utilize tissue engineering methods to create a neural scaffold that
will efficiently serve as a biomimetic stem cell niche for the next generation of stroke
treatment investigations. Through decellularization, we can utilize the native architecture
of porcine brains to generate niche neural scaffolds. This scaffold should contain an
intact matrix, be free of cells and DNA, have retained basement membrane proteins.
2.2.2 Aim II: Analyze Stem Cell Niche Potential of Scaffold In Vitro
Our goal is to determine if the novel scaffold created and characterized in Aim 1
is in fact a stem cell niche. Therefore, our scaffold must ultimately mimic native neural
tissue by producing un-aided neural differentiation and providing a suitable environment
for sustained neural-like cell survival and maintenance. Most notably, this involves
retaining high levels of viable cells and ensuring that these cells are retaining their
neural-like characteristics through protein expression analyses. Additionally, neural cell
morphologies and alignments must be considered.

14

2.2.3. Aim III: Establish Preliminary Efficacy of Niche Constructs In Vivo
Our goal is to employ the niche neural construct developed in specific aim 2 as a
stroke treatment that upon implantation, returns living neural tissue and therefore overall
function to areas compromised by stroke. Short-term, this involves improved motor and
sensory control; long-term, this involves brain tissue regeneration.

CHAPTER 3: MATERIALS AND METHODS
3.1 Experimental Methods
The following protocols were used in the creation and in vitro and in vivo testing
of our niche neural scaffolds and constructs.
3.1.1 Decellularization
Porcine brains were ordered from Animal Technologies Inc. (Tyler, Texas). The brains
were collected from animals aged 2+ years, and were removed leaving the carotid
arteries intact. The experimental protocol for immersion decellularization was modified
from DeQuach, Jessica A., et.al. and is as follows.21 There were no deviations from this
protocol.
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3.1.2. Histological Tissue Fixation
All tissues to be histologically processed were first fixed in 10% neutral buffered
formalin. Porcine scaffolds were cut as illustrated in figure 11A prior to tissue to
processing, embedding in paraffin wax, and sectioning at 5µm. Explanted rat brains
were cut into coronal thirds such that the implanted materials were confined to the
middle portion (as illustrated in figure 11B) prior to processing, embedding in paraffin
wax, and sectioning at 5µm.

Figure 11: Orientation of tissues prior to processing. Left, porcine scaffolds and fresh samples
were cut into 6 relatively equal sections. Right, rat explants were cut such that the implants were
confined to the middle section.

3.1.3 Hematoxylin and Eosin Sections
Hematoxylin and Eosin (H&E) staining is a commonly employed method of
generic cellular and matrix staining. The hematoxylin stains nuclei and other basophilic
substances blue, while the eosin stains cytoplasm and tissue elements various shades
of pink. Slides were stained according to the Richard-Allan™  H&E  protocol  listed  below.
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3.1.4  Masson’s Trichrome Sections
Masson’s   Trichrome   is   a   staining   method   typically   employed to clearly
differentiate between collagen, blue, and muscle and fibrous components, red, (cell
nuclei stain black).   Slides   were   stained   according   to   the   Poly   Scientific   Masson’s  
Trichrome Method listed below. Note that the sections were left in Aniline Blue solution
for 20 minutes.
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3.1.5 Bielschowsky Neural Stain Sections
The Bielschowsky Lester-King method is a silver staining technique employed in
the  diagnosis  of  Alzheimer’s  disease  due  to  its  deep  brown  staining  of  senile  plaques.  In
this case the stain was employed, because it clearly stains nuclei and neuronal axons
black (This allows analysis of cellular interactions as well as serves as an additional
decellularization assessment). White and gray matter stain yellow to brown. Sections
were stained according to the Newcomer Supply Lest-King method which is listed below.
Note that all glassware was cleaned using Hydrochloric Acid, 0.15% Aqueous Solution
and rinsed in at least six changes of distilled water prior to use. Sections were developed
for 6 minutes.
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3.1.6 Alcian Blue Sections
Alcian Blue is a staining method for glycosaminoglycans (GAGs) where cell
nuclei stain red, cytoplasm stains pink, and GAGs stain blue. Though concentrations and
types of GAGs change with development, the mature brain retains a large amount of
GAGs. The below protocol was utilized to visualize this GAG composition.
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3.1.7  Movat’s  Pentachrome  Sections
Movat’s  pentachrome  is  an  efficient  stain  utilized  to  clearly  differentiate  between  
five common matrix components. This stain is particularly useful in scaffold
characterization and analysis of tissue development. Cellular nuclei stain black, elastin
fibers stain purple-black, collagen stains yellow, ground substance (GAGs) stains blue,
and muscle/fibrinoid stain red.
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3.1.8 Luxol Fast Blue Staining
Luxol Fast Blue is a prominent method for staining myelin and Nissil substances
in neural and spinal tissue sections. In this method, myelinated fibers stain blue and
Nissil substances and nerve cells stain violet.

3.1.9 Immunohistochemical Examination
Immunohistochemistry (IHC) is a popular staining method for protein expression.
Positive staining, indicative of matrix or
cellular expression of the targeted protein,
appears brown. All antibody preparations
were made at the manufacturer (Abcam)
recommended dilution.
Table 1: List of all antibodies including serum and
antigen source.
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3.1.9.1 Manual Method
Table 1 lists all antibodies used during IHC assays. These same antibodies were
utilized in immunofluorescence staining (see section 3.1.15).
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3.1.9.2 Automated Method (Using the Leica Bond System)
The Leica Bond Max instrument preforms automated IHC using the highly
specific Leica polymer detection system. This method of IHC was used for all explant
IHC analyses.

3.1.10 Qiagen DNA Purification
The Qiagen DNeasy Blood and Tissue Kits is a silica-based DNA purification
system which prepares DNA samples for both qualitative and quantitative analysis. This
research employed the protocol for purification of total DNA from animal tissue, listed
below.
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3.1.11 Ethidium-Bromide DNA Agarose Gel Electrophoresis
Gel electrophoresis separates molecules (in this case DNA) by size and or
charge. An electric field is applied, and the negatively charged DNA molecules move
away from the edge of the gel producing bands. The below protocol was used for gel
preparation and analyses.

3.1.12 Nano Drop 200C Analysis
Nano Drop 200C utilizes very low volumes of purified DNA to generate
quantitative DNA measurements through UV absorbance. DNA absorbs light of
wavelength 260nm. The amount of light absorbed indicates increasing amounts of DNA
in the sample.
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3.1.13 Cellular Maintenance and Seeding
HADSCs
HADSCs (Invitrogen) were maintained with the manufacture recommended
media, MesenPRO. Cells were expanded until passage 3-6 prior to use in these studies.
HADSCs utilized during the in vivo studies were donated from LaCell LLC, and
maintained according to the previously described conditions.
Rat Cortical Astrocytes
Astrocytes (Invitrogen) were maintained with the manufacture recommended
medium, the Astrocyte Growth Medium Bulletkit ®. Astrocytes were expanded up to
passage 7 prior to use in these studies.
Cell Seeding
All cell types underwent the same drop-wise cell seeding method using their
respective mediums. Briefly, prior to seeding, cells were re-suspended in the total
volume of media necessary such that 2mL suspension/well (cells seeded onto plastic) or
105µL suspension/well (cells seeded onto scaffolds) was pipetted slowly over the top of
each lyophilized scaffold.
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3.1.14 Live/Dead Staining
Live/Dead staining is a common qualitative assessment of cell viability. Calcein
stains live cells a vibrant green via the enzymatic conversion of Calcein AM within cells
to Calcein. Ethidium homodimer enters damaged cell membranes and binds to any
remaining nucleic acids, producing red fluorescence.

3.1.15 Immunofluorescence
Immunofluorescence is a popular staining method for protein expression. Cells
that are expressing the protein will fluoresce light at a wavelength dictated by the
emission spectra of the secondary antibody, in this case green. All antibody preparations
were made at the manufacture (Abcam) recommended dilution.
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3.1.16 DAPI Staining
4', 6-diamidino-2-phenylindole (DAPI) is a popular counterstaining method in
fluorescent techniques. DAPI binds strongly to certain nucleic acid residues fluorescing
blue, making it a strong cell nucleus marker. DAPI counterstaining validates positive
immunofluorescence staining by co-localizing the staining with a cell nucleus. DAPI was
applied directly onto samples prior to fluorescent imaging.
3.1.17 2,3,5-triphenyltetrazolium chloride (TCC) Staining
TCC staining is a common method of confirming tissue infarction. TCC salts
react with dehydrogenase enzymes in cells resulting in a red-purple stain. Infarcted
tissues lack these enzymes, leaving the tissue a pale-cream color.
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3.2 Scaffold Creation and Characterization
Neural scaffolds were created following the previously described decellularization
protocol. Prior to use, all scaffolds were rinsed 3x with sterile PBS, followed by an
overnight rinse in sterile PBS, and 3x rinse with sterile PBS to ensure removal of storage
buffer prior to use in any assay or histological process.
Scaffold characterization involved histological examination to ensure removal of
cellular and DNA containing components as well as confirm the presence of an intact
extracellular matrix. Additionally, more specific stains were employed to determine the
matrix composition of the scaffolds and compare this composition with that of native
brain.
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Lastly, retention of key basement membrane proteins was examined. Collagen IV
and Laminin are commonly assessed basal lamina proteins, because as previously
described, they facilitate cell proliferation, differentiation, adhesion, and viability.
Additionally, Laminin is a known promoter of neural differentiation and GABAergic cell
proliferation.3 Retention of these proteins is key in the effort to produce a niche neural
scaffold, meaning a scaffold that acts as a stem cell niche by promoting unaided
differentiation of stem cells into neural cells and maintaining the viability and neurallikeness of these cells.
3.3 In Vitro Experimentation
The in vitro experimentation focused on determining the niche stem cell potential
of our scaffolds. Studies were devised such that potential niche stem cell groups were
directly compared to induced stem cells groups of similar conditions. Initial studies were
completed in plastic culture wells to establish base measurements of cell viability and
successful differentiation. Most preliminarily, the method of inducing cells via neural
induction was replicated to ensure our results would be comparable to the current
literature.
3.3.1 Cells Seeded onto Plastic
In Vitro Study 1
To confirm the efficacy of neural induction, human adipose derived stem cells
(HADSCs, Invitrogen) were seeded into tissue culture well plates at a seeding density of
1500cells / mm3. Cells were allowed 48 hours to adhere before replacing the MesenPRO
culture media with NIM. The NIM remained for 4hour, 24 hour, or 5 day time points after
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which time protein expression for neural markers and cell viability were analyzed through
immunofluorescence and Live/Dead staining, respectively. Controls for this study
included HADSCs with no induction step and rat cortical astrocytes (Lonza). All controls
were seeded at the same density as the test group and allowed 48 hours to adhere.
After 48 hours, protein expression for neural markers and cell viability were analyzed
through immunofluorescence and Live/Dead staining, respectively. An outline of the
study can be seen in figure 12.

Figure 12: Detailed explanation of study 1: cells seeded onto plastic.

In Vitro Study 2
In an effort to determine if the low viability associated with neural induction
results from a lack of nutrient supply, study 2 was completed following the exact
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methods described for the treatment group in study 1, except the NIM was replaced
daily.
3.3.2 Cells Seeded onto Scaffolds
In preparation for cell seeding, sterile scaffolds were cut into 5mm diameter
punches and spread throughout the base of one 96-well tissue culture plate well.
Scaffolds were frozen in -80°C overnight prior to lyophilization for 24 hours.
To allow direct comparisons between groups, the methods of studies 3 and 4
exactly mirror those of in vitro studies 1 and 2, respectively. A schematic of methods for
scaffold preparation and study 3 can be seen in figure 13.

Figure 13: Detailed explanation of study 3: cells seeded onto scaffolds.
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Study 5
To determine the stem cell niche potential of the scaffolds, HADSCs were
seeded into tissue culture well plates at a seeding density of 1500cells / mm3. Cells were
allowed 48 hours to adhere before replacing the MesenPRO culture media. This culture
media remained for 4hour, 24 hour, or 5 day time points after which time protein
expression

for

neural

markers

and

cell

viability

were

analyzed

through

immunofluorescence and Live/Dead staining, respectively. The positive control for this
study was rat cortical astrocytes (Lonza). Astrocytes were seeded at the same density
as the test group and allowed 48 hours to adhere. After 48 hours, protein expression for
neural markers and cell viability were analyzed through immunofluorescence and
Live/Dead staining, respectively. A schematic of the test group methods can be seen in
figure 14.

Figure 14: Detailed explanation of study 5: cells seeded onto scaffolds.
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Study 6
In an additional effort to determine if the viability of HADSCs was being affected
by a lack of nutrient supply, study 6 was completed following the exact methods
described for the treatment group in study 5, except the MesenPRO was replaced daily.

3.4 In Vivo Experimentation
3.4.1 Overview
The goal of the in vivo experimentation was to confirm the niche neural
construct’s efficacy in stroke treatment. There is no in vitro model for stroke. Rodents,
more specifically rats, are the most commonly used animal models for stroke due to the
similarities between their intracranial circulation system and that of humans, the
abundance of available neurochemical data, and the lack of rete mirabile.34, 35
The most widely used animal stroke model is middle cerebral artery occlusion
(MCAO). This method most commonly involves a mid-line neck incision to expose the
internal and external carotid arteries followed by suture introduction through the external
into the internal thereby blocking blood flow through the middle cerebral artery. Transient
introduction of the suture for a 2-hour period yields the most reproducible infarct while
minimizing animal death. 25, 36-38 The general schematic of this procedure can be seen in
figure 15.
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Figure 15: Intraluminal suture method of middle cerebral artery
occlusion to induce stroke.

Functional recovery in rodent stroke models has been seen as a result of the
intracranial administration or intravenous administration of stem cell therapies.
Intravenous administration tends to fuel cell death as well as lead to unwanted side
effects in other areas.19 However, both delivery methods show the most promise with
administration 1 day post-stroke and 7 days post stroke.19, 39 Functional recovery can be
evaluated   through   a   variety   of   testing   methods,   but   certain   tests   such   as   the   “rotarod”  
and  “water  maze”  are known to yield a larger percentage of false positives due to their
target of very specific brain regions, while the neural severity scoring system, adhesiveremoval, food grabbing, and limb placement tests have yielded more positive results,
especially during long-term animal monitoring.17,

19, 40-44

Due to the immune-privileged

location of the stroked brain, a growing number of studies are employing the use of
human cells in rodent models without antigenic concerns; this approach also supports
the eventual adoption of the treatment in a translational research scenario.16, 17, 20, 40, 45
The in vivo study methods employed in this research were designed to confirm
our ability to successfully induce stroke in our rodent model, to validate a method for
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niche   neural   construct   delivery,   and   to   evaluate   animals’   functional   recovery   posttreatment. All components of the in vivo study were completed in accordance with
Clemson University AUP2013-032 and IBC2010-28.

3.4.2 Stroke Induction
22 middle-aged female Wistar rats underwent 2 hour transient MCAO via the
intraluminal suture method (described in detail below).

The sutures employed for

occlusion were 3-0 monofilament nylon sutures coated with silicon (Docool Corp.) that
were blunted via introduction into flame prior to insertion.

Immediately after closing, 6 rats were euthanized and their brains collected for
TCC Staining to confirm infarction and to determine an average infarct area. The
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location of the craniotomy incisions and tissue removal were based off of this average
infarcted area.

3.4.3 Niche Neural Construct Delivery (Craniotomy)
One day post-MCAO, 8 rats underwent niche neural construct implantation via
craniotomy. Briefly, the top of the head of each rat was shaved prior to making an
incision in the top of the head. The skin was peeled back, and a 5mm square of bone
was removed from the skull using a dental drill. Then, light suction was introduced,
removing the damaged tissue from the brain.

Figure 16: Diagram of average infarcted area as determined by TCC staining and tissue intended to be removed prior to construct
delivery.

Niche neural constructs were then inserted filling the created void. A piece of
Surgicel (Ethicon) was placed over the top of the brain. The skin was folded back over
the skull, and each rat was sutured closed.
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These niche neural constructs were prepareed according to the methods
described in section 3.3.2. The constructs are representitive of the study 6 group at a 4
day timepoint.

The only deviation from the previously cited methods was that the

hunman adipose stem cells were verified to be from male donors and were obtained
from LaCell LLC.

3.4.4 Behavioral Testing
To assess functional recovery post-stroke, all rats underwent behavioral testing
which consisted of modified neural severity scoring (mNSS). The mNSS is a
combination of sensory and motor analyses where one point is awarded for abnormal
function (i.e. a score of 0 indicates perfect function). This examination required no
training prior to administration. The mNSS was administred the night prior to stroke
induction, 1 hour post-stroke, and weekly thereafter to obtain baseline measuremets,
assess immediate functional damage, and monitor functional recovery, respectively. The
mNSS protocol utilized in these assessments is listed below.
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3.4.5 Animal Sacrifice
Animals were euthanized via deep isoflurane anesthesia followed by
exsanguination. Death was confirmed through bilateral pneumothorax. Rat brains were
carefully removed via post-mortem craniotomy and immediately placed in formalin.
(Note: n=6 brains required for TCC staining were not placed in formailn).
3.4.6 Explant Analysis
Explants were prepared for histology and stained as previously described in
sections 3.1.2-3.1.9.
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CHAPTER 4: RESULTS

4.1 Scaffold Creation and Characterization
Fresh porcine brains were decellularized according to the methods described in
section 3.1.1. Macroscopic changes from fresh to decellularized specimens are
observed in figure 17. The decellularized scaffold appeared transparent and showed
significant mass loss 95.97% ± 0.28 (n=3).

Figure 17: Qualitative Scaffold Analysis. A) Fresh porcine brain. B) Decellularized
scaffold. C) DNA gel indicating significant reduction from fresh tissue to scaffolds.

Qualitative DNA analysis through Ethidium-Bromide DNA Agarose Gel
Electrophoresis (figure #17C) shows a significant reduction in DNA from fresh to
decellularized scaffolds. As seen in figure 18, analysis utilizing the Nanodrop 200C
quantified this reduction from 818.5 ± 66.4 ng/mg in fresh tissue to 4 ± 4.0 ng/mg in the
scaffolds (P<0.005).
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Figure 18: Quantitative DNA Analysis via Nanodrop 200C indicating >99% reduction
in DNA content from fresh to decellularized tissues.

IHC for neural proteins was employed as an additional measure of successful
decellularization. Figure 19 illustrates the complete removal of all Nestin, Map-2, and
GFAP staining after decellularization.

Figure 19: Histological Decellularization Confirmation. Complete removal of key neural cell proteins is observed in
decellularized scaffolds.
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Further characterization was accomplished through histological staining (figure
20-22). Through H&E, it was clear the scaffold consisted of an intact matrix and was free
of   all   cellular   components.   Masson’s   Trichrome   staining indicated the scaffold was
primarily composed of collagen. The presence of what appeared to be intact blood
vessels was also observed. Additionally through Bielschowsky staining, complete
removal of neural fibers was observed.

Figure 20: Preliminary Histological Characterization. Left, H&E staining indicating scaffolds contained an intact
matrix  with  no  cellular  remnants.  Middle,  Masson’s  Trichrome  staining  indicating  this  matrix  was  primarily  collagen.  
Right, Bielschowsky neural stain confirming scaffolds did not contain neural fibers.

A more in depth understanding of the scaffold composition was obtained through
Movat’s   Pentachrome   and   Alcian   Blue   staining. Movat’s   Pentachrome   staining   was  
consistent   with   Masson’s   Trichrome   indicating   the   scaffold   is   primarily   composed   of  
collagen. However, significant portions of the scaffold also appeared to stain for ground
substance, supposedly GAGs, and elastin (figure 21). Alcian blue confirmed the
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presence of GAGs intermixed with
other matrix components in fresh
tissue. Consistent   with   the   Movat’s  
staining,

limited

GAG

fractions,

primarily near the outer edges of the
scaffold,

were

retained

through

decellularization.
Figure   21:   Movat’s Pentachrome Staining indicating the
scaffold, though primarily collagen, had retained elastin and
ground substance (GAGs).

Figure  22:  Histological  Examination  Continued.  Left,  Movat’s  Pentachrome  staining  confirming  
the scaffold was primarily collagen matrix. Right, Alcian blue staining indicating there was
minimal retention of GAGs near scaffold edges.
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Lastly, the scaffold was examined for retention of key basement membrane
proteins. Figure 23 shows the successful retention of both collagen IV and Laminin.

Figure 23: Basement Membrane Analysis. Left, IHC for collagen IV and right, IHC for Laminin confirming
retention of both these key basement membrane proteins within the scaffolds.

4.2 In Vitro Experimentation
4.2.1 Viability Assessment
Qualitative assessment of cell viability through Live Dead staining of the positive
control, astrocytes, showed predominantly viable cells (Figure 24). Quantitative analysis
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indicated 87% viable cells after 24 hours of culture in well plates compared to 95%
viability when astrocytes were seeded onto scaffolds.

Figure 24: Astrocyte Viability Assessment through Live Dead staining indicating 87% viable cells seeded onto
plastic compared to 95% viability when seeded onto scaffolds.

Similar assessment of cell viability in the test groups of NIM treated HADSCs at 4 hours
showed a significant population of live cells (figure 25).

Figure 25: 4 Hour Viability Assessment. Live Dead staining indicated significant populations of viable cells across all
test groups.
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Quantitative assessment of this viability is seen in table 2.

Table 1: 4 Hour Quantitative Viability Assessment. There was comparable viability between No NIM and the respective
NIM groups. Overall, strong viability was observed across all groups.

By 24 hours, the remaining cells were almost all viable. However, overall there were
fewer cells observed throughout the specimens, particularly the NIM groups seeded into
well plates.

Figure 26: 24 Hour Quantitative Viability Assessment. There was an increase in viability between No-NIM and the
respective NIM groups. Overall, strong viability was observed with the exception of the NIM treated group seeded into
well plates.
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Quantitative assessment of this viability is seen in table 3.

Table 2: 24 Hour Quantitative Viability Assessment. There was an increase in viability between No-NIM and the
comparable NIM groups. Overall, strong viability was observed with the exception of the NIM treated group seeded into
well plates.

Finally by day 5, all NIM groups were greatly compromised compared to non-NIM
treated groups. In the NIM groups seeded onto plastic, almost no viable cells were
observed; whereas NIM groups seeded onto scaffolds retained populations of viable
cells.

Figure 27: 5 Day Quantitative Viability Assessment. All NIM groups showed extremely compromised viability. Non-NIM
treated groups showed significant populations of viable cells.
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Quantitative assessment of this viability is seen in table 4.

Table 4: 5 Day Quantitative Viability Assessment. All NIM groups were extremely compromised. However, the NIM
groups seeded onto scaffolds showed significantly increased viability compared to cells seeded into well plates. All
scaffold seeded groups had strong viability, with a clear increase in viability for the group where the culture media
was replaced.

The quantitative viability for NIM groups is summarized in the below graph. All
NIM groups where cells were seeded onto scaffolds showed greater cell viability than
their counterparts seeded onto plastic. Significantly, by 24 hours there was statistical
difference between scaffold and both plate groups. However, no statistical difference
was observed between groups seeded onto scaffolds. By day 5 there was a clear
increase in viability, 36-49% compared to 0-5%, between scaffold-seeded and well plateseeded groups. Additionally, the statistical difference between scaffold and both plate
groups still holds. Most notably, by 5 days regardless of environment, replacing the NIM
resulted in statistically different (lower) viability.
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Figure 28: NIM Viability Summary. By 24 hours there was statistical difference between scaffold and both
plate groups. This statistical difference held at 5 days with the addition of statistical difference between the
scaffold and scaffold replaced group. Significantly, regardless of environment, replacing the NIM yielded
statistically different (lower) viability.

4.2.2 Cells Seeded onto Plastic
Quality of differentiation was assessed though immunofluorescence for neural
proteins Nestin, Map-2, and GFAP. Negative controls for all immunofluorescence studies
are provided in the top left corner of each image.
The negative control, HADSCs, seeded into well plates very minimally expressed
Nestin, expressed nuclear Map-2, and did not express GFAP (See Appendix A).
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The positive control, astrocytes, seeded into well plates very minimally expressed
Nestin, did not express cytosolic Map-2, and vibrantly expressed GFAP.

S

Figure 29: Astrocyte Protein Expression on Plastic. Astrocyte controls expressed small amounts of Nestin, no
cytosolic Map-2, and significant amounts of GFAP.

Study 1
At 4 hours, NIM induced cells seeded onto plastic minimally expressed Nestin,
Map-2 expression was beginning to transition from nuclear to cytosolic, and no GFAP
expression was observed.

Figure 30: Study 1 – Protein Expression at 4 hours. Nestin and Map-2 were minimally expressed by test group cells.
No GFAP expression was observed.

By 24 hours, expression of both Nestin and Map-2 had significantly increased.
Additionally, cells began to express GFAP. Notably, all expression was co-localized with
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a cell nucleus. There were also indications of morphological changes including the
development of cytosolic processes.

Figure 31: Study 1 – Protein Expression at 24 hours. Expression of all markers was observed. Map-2 expression had
transitioned from nuclear to cytosolic. Additionally, the development of cytosolic processes was observed.

By 5 days, expression was virtually non-existent. Additionally, there were almost
no intact nuclei indicating no viable cells.

Figure 32: Study 1 – Protein Expression at 5 Days. No expression was observed. Additionally, very few viable cell
nuclei were observed.

Study 2
By 4 hours, NIM induced cells where the NIM was replaced daily expressed
Nestin and cytosolic Map-2. However, no GFAP expression was observed.
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Figure 33: Study 2 – Protein Expression at 4 Hours. Nestin and cytosolic Map-2 expression were observed. However,
no GFAP expression was observed.

By 24 hours, expression of Nestin and Map-2 lessened, but GFAP expression
was now observed. Across all markers, unfavorable morphological changes were
observed.

Figure 34: Study 2 – Protein Expression at 24 Hours. Expression of all markers was visible. No favorable morphological
changes were observed.

By 5 days, neither marker expression nor viable nuclei were observed.
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Figure 35: Study 2 – Protein Expression at 5 Days. Neither marker expression nor viable nuclei observed.

4.2.3 Cells Seeded onto Scaffolds
The positive control, astrocytes, seeded onto scaffolds very minimally expressed
Nestin, did not express Map-2, and vibrantly expressed GFAP.

Figure 36: Astrocytes Seeded onto Scaffolds. Minimal Nestin, no Map-2, and significant GFAP expression were
observed.

Study 3
For NIM induced cells seeded onto scaffolds at 4 hours, expression of all
markers was observed. Significantly, MAP-2 expression transitioned from nuclear to
cytosolic.
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Figure 37: Study 3 – Protein Expression at 4 Hours. Expression of all markers was observed.

By 24 hours, expression of all markers had been maintained. Significantly,
cytosolic Map-2 expression was still observed.

Figure 38: Study 3 – Protein Expression at 4 Hours. Expression of all markers was maintained.

At 5 days, there was still fluorescence indicating expression of all markers.
Though the fluorescence appeared very faintly, there was cytosolic Map-2 expression.

Figure 39: Study 3 – Protein Expression at 5 Days. Expression of all markers was still observed.
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Study 4
For NIM induced cells seeded onto scaffolds where the NIM was replaced daily,
expression of all markers was observed at 4 hours. Significantly, MAP-2 expression
transitioned from nuclear to cytosolic.

Figure 40: Study 4 – Protein Expression at 4 Hours. Expression of all markers was observed. Significantly, Map-2
expression was cytosolic.

By 24 hours, expression of GFAP appeared to increase. However, the
morphological changes and alignment observed in the Nestin and Map-2 staining at 4
hours were no longer present. Additionally, it is unclear if cytosolic Map-2 expression
was maintained.

Figure 41: Study 4 – Protein Expression at 24 Hours. Expression of all markers was observed. It is unclear if cytosolic
Map-2 expression was maintained.
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By 5 days, very minimal Nestin and GFAP expression were observed. No distinct
cytosolic Map-2 staining was present.

Figure 42: Study 4 – Protein Expression at 5 Days. Minimal expression of Nestin, nuclear Map-2, and GFAP was
observed.

Study 5
At 4 hours, HADSCs seeded onto scaffolds with no induction step expressed
Nestin, nuclear Map-2, and minimal GFAP. Additionally, there were clear morphological
changes demonstrating the development of numerous cytoplasmic processes.

Figure 43: Study 5 – Protein Expression at 4 Hours. HADSCs seeded onto scaffolds expressed Nestin, nuclear Map-2,
and minimal GFAP. Significant morphological changes had occurred, as illustrated by the development of numerous
cytoplasmic processes in cells staining for Nestin.
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By 24 hours, HADSCs were expressing all neural markers (Map-2 expression
had transitioned to cytoplasmic expression). Significant cytoplasmic processes and
cellular interactions were also noted.

Figure 44: Study 5 – Protein Expression at 24 Hours. HADSCs seeded onto scaffolds expressed all markers and
continued to show morphological characteristics of neural-like cells.

By 5 days, expression of all markers was maintained and even increased.
Additionally, cellular processes continued to develop and cells began to align tip-to-tail.

Figure 45: Study 5 – Protein Expression at 5 Days. HADSCs seeded onto scaffolds exhibited heightened expression of
all markers. Additionally, cellular alignment is observed and morphological changes were maintained.
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Study 6
At 4 hours, HADSCs seeded onto scaffolds where the MesenPRO cell culture
media was replaced daily expressed Nestin, nuclear Map-2, and minimal GFAP. As in
study 5, there were morphological changes demonstrating the development of numerous
cytoplasmic processes.

Figure 46: Study 5 – Protein Expression at 4 Hours. HADSCs seeded onto scaffolds expressed Nestin, nuclear Map-2,
and minimal GFAP.

By 24 hours, cells were expressing all markers. Map-2 staining had transitioned
from nuclear to cytosolic expression. Additionally, morphological changes were
maintained.

Figure 47: Study 5 – Protein Expression at 24 Hours. Cells expressed all markers and had maintained morphological
changes.
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Expression of all markers was not only maintained but appeared to increase by
day 5. Significant cellular alignment as well as maintenance of developed projections
was observed.

Figure 48: Study 5 – Protein Expression at 5 Days. An increase in expression of all markers was observed.
Additionally, cells began to align and maintained morphological changes.

Phase contrast images overlayed with the calcein portion of a Live Dead stain
highlighted these maintained morphological features. Cell bodies as well as cellular
projections were aligning to the fibers within the scaffold.

Figure 49: Cellular Alignment to Scaffold Fibers. Phase contrast images overlayed with the calcein portion of a Live
Dead stain clearly indicated cells (A) and cellular projections (B) were aligning to scaffold fibers.
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4.3 In Vivo Experimentation
4.3.1 Stroke Induction
The two hour transient MCAO procedure described in section 3.4.2 was
completed on all 22 rats. A summary of the operation is seen in figure 50. Briefly, the
rats were anesthetized, a mid-line neck incision was made, and the glandular tissue was
retracted to reveal the common, external, and internal carotid arteries. The internal
carotid artery was clamped and the external carotid was ligated. An incision was made
into the external carotid and the suture was introduced into the internal carotid via the
external carotid artery. The clamp was removed and the rat was stapled closed for the
two hour occlusion period. After 2 hours, the rat was re-anesthetized and opened, the
suture was removed to allow reperfusion, and the rat was sutured closed (not pictured).

Figure 50: MCAO Operation. Two hour transient MCAO was performed on all 22 rats as described in section 3.4.2.
Briefly, a midline neck incision was made and the common, external, and internal carotid arteries were isolated. After
ligating the external carotid, a small incision was made and the suture was introduced for a two hour period. After two
hours the suture was removed to allow reperfusion.
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Following MCAO stroke induction, 6 rats were
euthanized and their brains collected for TCC staining.
Figure 51 shows a representative TCC stained brain
section. The pale cream color of the brain visible
through TCC staining indicated successful stroke
induction. These staining results yielded the average
infarcted area and therefore the anticipated location of

Figure 51: TCC Staining. The cream
color in the upper right indicated
successful stroke induction.

construct implantation illustrated in figure 16.
The remaining 16 rats were divided into 2 groups, MCAO control (n=8) and
treatment (n=8). N=4 control rats and N=2 treatment rats died either during or as a result
of complications from surgery.

4.3.2 Niche Neural Construct Delivery (Craniotomy)
The remaining N=6 treatment group rats underwent niche neural construct
implantation. N=1 rats experienced an anesthesia related death. Niche neural construct
delivery was successfully accomplished as described in section 3.4.3. Figure 52
illustrates this process. Briefly, rats were anesthetized, an incision was made on the top
of the head, and the skin was retracted. Next, a small ~25mm2 section was removed
from the skull using a dental drill. Damaged brain tissue was identified, as it was
texturally different from the healthy tissue. Light suction was introduced to these brain
areas removing the necrotic tissues. The pre-prepared sterile niche neural constructs
were introduced into this void. Surgicel was placed over the operated area, and the rat
was sutured closed. This method allowed for the creation of an injury specific void and
thus maximal treatment delivery.
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Figure 52: Niche Neural Construct Delivery via Craniotomy. Construct delivery was accomplished as described in
section 3.4.3. Briefly, a small ~25mm2 skull fragment was removed and light suction was introduced to the damaged
brain areas. A Niche neural construct was placed into the created void, Surgicel was placed over this area, and the rat
was sutured closed.

4.3.3 Behavioral Testing
Behavioral testing was completed as described in section 3.4.4. Figure 53 shows
the baseline (week -1), post-stroke (week 0), and recovery (up to 4 weeks) of each rat
surviving to the 4 week time point. Each rat began with perfect function, but this function
decreased from 4-10 points post-stroke, another indication the rats were successfully
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stroked. Over the four week period, the treatment group (purple colors) had an overall
more consistent and better recovery than the stroke controls (orange colors).
Figure 53 shows the average mNSS score of each group over the 6 time points.
Post stroke scores between groups were not statistically different. Over the 4 week
recovery period, the control group exhibited what appeared to be minimal improvement
eventually plateauing; however, there is no statistical difference between week 0 and
any recovery week time point (P>0.1). The treatment group exhibited rapid and
consistent improvement over 4 weeks. This improvement is statistically different from
week 0 beginning at the 2 week time point (P<0.05). Similarly, the improvement of the
treatment group is statistically different from that of the control group beginning at the 2
week time point (P<0.05).

Figure 53: mNSS Scores by group. The treatment group is statistically different from the control group beginning 2 weeks
post stroke (P<0.05). Additionally, though the control group appeared to improve, there is no statistical difference
between control group scores at any time point (P>0.1). Contrastingly, the treatment group scores became statistically
different from the week 0 score at the 2 week time point (P<0.05).
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4.3.4 Explant Analysis
Control (Stroke) Group
Histological analysis showed that at 1 week post stroke, rat brain tissue was
extremely damaged. The tissue did not stain well, and it showed initial signs of
degradation. By 4 weeks, most of the tissue had been degraded leaving a void of tissue
within the rat brain.

Figure 54: Control Group Histology. Overall, the tissue looked extremely damaged and stained poorly compared to
healthy tissues. At 1 week, there were signs of degradation, and by 4 weeks most of the tissue had degraded leaving
a void.
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Figure 55 shows more matrix component specific staining. A similar trend of
degradation is observed.

Figure 55: Control Group Histology Continued. At 1 week, there were signs of degradation, and by 4 weeks most of
the tissue had degraded leaving a void.

Treatment Group – 1 Week Matrix Analysis
At one week, the implanted niche neural constructs did not show significant
degradation or change in overall matrix composition.
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Figure 56: Week 1 Treatment Group – Matrix Analysis. Niche neural constructs did not show significant degradation.
Additionally, the matrix remained almost entirely collagen.

Movat’s   Pentachrome   staining   revealed   the   matrix   still   contained   elastin.   Alcian  
Blue staining indicated that GAG formation was occurring between scaffold edges.

Figure 57: Week 1 Treatment Group – Matrix Analysis Continued. Niche neural constructs had
retained elastin, left. At right, new GAG formation was occurring between scaffold edges.
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Treatment Group – Week 4 Matrix Analysis
As seen in H&E staining, by 4 weeks, the constructs had large amounts of tissue
ingrowth. This tissue appeared extremely disorganized, and it was not primarily
composed of collagen.

Figure 58: Week 4 Treatment Group – Matrix Analysis. There was extensive tissue ingrowth within the constructs. This
tissue growth did not appear organized, and it was not primarily composed of collagen.
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Staining   with   Movat’s   Pentachrome   confirmed   that   the   tissue   ingrowth   was   not  
collagen. Staining with Alcian blue indicated GAGs comprised a significant portion of this
new matrix.

Figure 59: Week 4 Treatment Group – Matrix  Analysis  Continued.  Movat’s  Pentachrome  staining  confirmed  the  lack  of  
collagen in the newly formed tissue. Alcian Blue staining confirmed a large portion of this tissue was GAGs.
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Vascular Assessment
Embedded in healthy brain matrix are numerous small blood vessels. As seen in
figure 60, these vessels are typically 20µm in diameter.

Figure 60: Healthy Brain Vasculature. Cerebral blood vessels differ in size and orientations, but they are primarily
20µm in diameter.

H&E staining of 4 week explants showed a similar network of small diameter
vessels. Similar to the vasculature of healthy brain tissue, these vessels were 20µm in
diameter on average. These vessels were distributed rather evenly across the construct,
and contained red blood cells; no leukocytes were visible within the lumen of these
vessels.
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Figure 61: 4 Week Construct Vasculature. An evenly distributed network of blood vessels was observed within the
constructs. These vessels were roughly the same size as the average healthy brain vessels.

Cellular Analysis
IHC for neural markers Nestin, Map-2, and GFAP revealed both Nestin and Map2 staining within the construct regions at 4 weeks. However, no GFAP expression was
observed. Both Nestin and Map-2 expression appeared in cell bodies as well as in the
matrix surrounding the cells.
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Figure 62: IHC for Neural Markers. Expression of Nestin and Map-2 was observed throughout the construct area. No
GFAP expression was seen in the construct.
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Figure 63: Quantitative Neural marker Expression. Expression of Nestin (P<0.0005)
and Map-2 (P<0.001) increased from 1 to 4 weeks. No GFAP expression observed at
either time point.
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In depth analysis of cell types present in the construct area at 4 weeks was
obtained through high magnification of H&E staining. Six prominent cell types were

Figure 64: Cell Phenotype Analysis. Middle, a low magnification H&E image with boxes indicating different cell types
observed within the construct area. Bottom, high magnification images representative of these cell types. Top, the
equivalent cell type found within a healthy rat brain. Note: cell type E was not observed in the healthy brain.

observed, named A-F. Morphologically similar cells were identified in the healthy brain;
however, cell type E was not located. Morphological analysis reveals cell types A, B, and
F match a neuron phenotype. Cell types C and D appeared to be a form of accessory
cell. Lastly, cell type E appeared to be a leukocyte.
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In depth analysis was performed on potential neural cell types in an attempt to
confirm their identity. Analysis of cell types A, B, and F is seen below. Cell types A, B,

Figure 65: Analysis of Cells of Neuron Phenotype. Through H&E cells morphologically appeared to
be neurons. Map-2 staining confirms expression of Map-2 is all these cell types. Bielschowsky
staining confirms cell types A and B possess Nissil bodies.
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and F are morphologically characteristic of
neurons. Cell type F, the stereotypically
recognized neuron has two orientations,
both are represented in the H&E and Map2 stains. These neurons stained very darkly
and did not necessarily have a visible
nucleus and or nucleolus. They did have
visible projections, stained for Map-2 along
the length of the cell, but they did not stain
for

Nissil

bodies.

Cell

type

B

is

characteristic of a cross section of an axon,
where the axon appears rather centrally
and is surrounded by Nissil bodies. Both
cell type A and B tended to have concentric
Map-2 staining around the cell body. Cell
type A was significantly larger than the
other cell types and the nucleus and
nucleolus were along the periphery.
Cells with characteristic accessory
cell phenotypes underwent similar analysis.
Morphologically, cell type C was much
smaller than cell type D. Both of these cells
were typically found in close proximity to
cells

phenotypically

characterized

as
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Figure 66: Analysis of Accessory Cell Phenotypes.
Both cell types did not express Map-2 or GFAP. An
astrocyte is represented and stained with GFAP to
allow comparison between cell types C and D and
astrocytes.

neurons. As illustrated in figure 66, neither cell type stained for Map-2 or GFAP. In
figure 66, an astrocyte from a healthy brain is represented as the healthy cell for GFAP
staining to allow comparison between cell types C&D and astrocytes.

HADSCs
Explants from both time points underwent double staining immunofluorescence
for human mitochondria (expressed by the HADSCs) and Map-2 (expressed by HADSCs
seeded onto niche neural constructs prior to implantation).

Figure 67: Human mitochondria Map-2 Double Stain. Some individual cells expressed both human mitochondria as
well as Map-2. A notable amount of cells also solely expressed Map-2.Green indicates Map-2. Red indicates human
mitochondria. Blue indicates DAPI nuclear staining.
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Overlays of staining indicated that some individual cells were positive for both Map-2
and human mitochondria. However, a notable number of cells expressed only Map-2.
See Appendix A for additional double staining.

The Interface
Analysis of the construct – brain tissue interface revealed no identifiable capsule
formation. The construct appeared well integrated with the surrounding host tissue.
Additionally, this integrated region was vascularized (indicated by the arrows in figure
68).

Figure 68: Histological Examination of the Interface. The construct is well integrated with the host tissue with no
identifiable fibrous capsule formation. The area is vascularized as indicated by arrows.

Analysis  through  Movat’s  Pentachrome  and  Alcian  Blue  yielded  similar  results.  In  
both  Movat’s  and  Alcian  staining,  some  cells  were  oriented  orthogonal  to  the  interface,  
appearing to bridge the gap between construct and host tissue. Additionally, high
magnification Alcian Blue staining showed neurons (indicated by arrows) at and on both
sides of the interface.
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Figure 69: Histological Examination of the Interface Continued. Some cell bodies were orthogonal to the interface,
bridging the construct and host tissue. High magnification Alcian Blue staining showed neurons at and on both sides
of the interface.
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IHC for neural markers confirmed that the majority of cells at and on both sides of
the interface stained positively for Nestin and Map-2. GFAP expression was only visible
on the host tissue side of the interface.

Figure 70: IHC for Neural Markers at the Interface. The majority of cells at and surrounding the interface expressed
Nestin and Map-2. Specifically, neurons were visible at the interface (indicated by the box). GFAP expression was
only observed on the host-tissue side of the interface

Significantly, there was no evidence suggesting reactive astrocytes had formed a
glial scar surrounding the construct. The number of astrocytes nearing the interface was
consistent with healthy brain tissue.

Figure 71: GFAP Expression at the Interface. The number of cells expressing GFAP near the interface (middle) is
consistent with that of healthy brain tissue (left). (Right) Extremely high levels of GFAP expression near the edge of a
4 week control group explant.
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CHAPTER 5: ANALYSIS AND DISCUSSION

5.1 Neural Scaffolds
A neural scaffold was successfully created through the Decellularization of a
porcine brain. As expected, though this process the scaffold lost significant mass, and
both qualitative and quantitative analysis confirmed a significant reduction in DNA.
Additionally, IHC staining for neural cell markers confirmed complete lack of expression
indicating no cellular or protein remnants in the decellularized scaffolds.
Histological characterization of the scaffolds immediately confirmed an intact
matrix with the absence of all cell bodies,   nuclei,   and   neural   fibers.   Both   Masson’s  
Trichrome   staining   and   Movat’s   Pentachrome   staining   indicated the scaffold’s   primary  
composition was   collagen.   However,   Movat’s   staining   revealed retention of the fibrous
protein elastin and GAGs (confirmed with Alcian Blue staining).
Lastly, IHC for basement membrane proteins confirmed the retention of collagen
IV and Laminin within the matrix. Staining primarily occurred around what appear to be
intact blood vessels. All scaffold characterization and analyses support   the   scaffold’s  
ability to serve as a non-cytotoxic niche for stem cells.

5.2 Niche Neural Constructs
To  replicate  the  gold  standard  in  neural  induction,  Woodbury’s  NIM  protocol  was  
utilized. This protocol calls for a 24-hour pre-induction step consisting of DMEM, 20%
fetal   bovine   serum,   and   1mM   β-mercaptoethanol. However, after 24 hours in this
medium cells had aggregated and detached from the plastic. Subsequent studies did not
utilize this pre-induction step with seemingly no differentiation repercussions. Woodbury
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did not monitor cell viability over the course of his study, so our results were compared
to Safford and Qian, two publications with induction mediums very similar to the one
utilized in this research. By 5 days, Safford reported 35% viability and by 7 days Qian
reported 5% viability. The viability results represented in tables 2-4 are slightly lower
than Safford by 5 days likely due to the fact that Safford did not employ DMSO, a known
cytotoxic cellular environment, in his induction approach. Overall, the values presented
in this research fall within close proximity to published results.
The immunofluorescence results for cells seeded onto plastic showed significant
morphological changes as early as 24 hours post-induction. Expression of all markers
was observed at this time point, but due to almost complete cell death it is unknown if
this expression was maintained to day 5. Overall, the efficacy of the NIM protocol was
confirmed and a baseline for construct assessments established.
To our knowledge, no publication has examined the effect of changing out the
NIM on a regular basis throughout a short-term study. Our hypothesis was that the
extremely poor viability associated with NIM induction may be due to a lack of nutrient
supply, and that the cells may be dying for these reasons and not solely due to the
harshness of the chemical environment. Our hypothesis was proven false, as replacing
the NIM resulted in even poorer cell viability. By day 5 statistical difference between NIM
and NIM replaced groups was observed. Additionally, the overall neural differentiation of
these cells past 4 hours was quite poor. It is likely that the waning viability of the cells
contributed to this lack of morphological change and cellular interaction.
Since neural induction is a widely characterized and established approach in the
neural regeneration field, it was necessary to determine if this approach is compatible
with our neural scaffolds. This also helped establish claims that the scaffold was in fact
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capable of maintaining neural-like cell life. Scaffolds were successfully seeded with NIM
induced cells. Initially there was no deviation in cell viability from groups seeded onto
plastic. However, as early as 24 hours there was statistical difference between the
viability of cells seeded onto scaffold vs. cells seeded onto plastic. Significantly, over
90% of these cells had remained viable. Contrary to the established inverse relationship
between cell viability and quality of induced differentiation, the quality of differentiation of
these cells was not lessened. From 4 hours to 5 days, expression of all markers had
been maintained. By 5 days, there is a >8x increase in viability observed when cells are
seeded onto scaffolds. Again, the success of differentiation was not hindered as a result
of this viability. Most significantly, the Map-2 expression observed was still cytosolic
indicating cells were progressing towards a neuron lineage.
We then hypothesized that changing out the NIM would have similar negative
effects seen with cells seeded on plastic, but that the scaffold could mitigate some of
these effects, still showing an increase in cell viability with less compromised quality of
differentiation. As figure 28 illustrates, there was similar viability between scaffold
seeded NIM and scaffold seeded NIM replaced groups at 24 hours, but by 5 days
statistical difference was observed. However, by 5 days, the scaffold seeded NIM
replaced group was still 7x greater than either group where cells were seeded onto
plastic. This indicates that the scaffold does mitigate but not completely alleviate the
viability limitations of replacing the NIM. The quality of differentiation of these cells was
also mitigated but not completely maintained. By 5 days, marker expression was faint
but still present (compared to completely absent in plastic seeded groups), specifically
cytosolic Map-2 expression was no longer present.
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HADSCs with no induction step were seeded onto scaffolds and maintained with
their manufacture recommended media to examine the stem cell niche potential of the
scaffold. We hypothesized these cells would show significantly higher viability than any
of the previous groups at all time points. Some decrease in viability was expected due to
a lack of nutrient supply. Additionally, the scaffold should promote unaided differentiation
of the seeded cells into neural-like cells. Viability assessments confirmed only a slight
decrease in cell viability (to 84%) over the 5 day period. Protein expression analysis
confirmed expression of all markers as early as 4 hours. By 24 hours this expression
was maintained and Map-2 expression had transitioned from nuclear to cytosolic. In
contrast to all previous results, the 5 day time point exhibited the most successful
differentiation with all markers being expressed at a higher intensity. Additionally,
significant morphological changes, visible as early as the 4 hour time point, had also
been maintained. The cells also appeared to exhibit varying forms of alignment. This
evidence confirms that the previously described tissue engineered scaffold reseeded
with HADSCs produces a niche neural construct.
In an effort to provide optimal conditions for survival of seeded cells, we
hypothesized that replacing the MesenPRO medium would result in an increase in
overall cell viability without compromising differentiation, morphology, and alignment. An
increase from 84% to 93% in cell viability was observed. As expected, the quality of
differentiation also appeared to increase with each time point, culminating in the most
promising expression at day 5. By 5 days the cells showed cytosolic expression of all
markers, significant interaction and alignment, and morphological changes. Interestingly
this alignment was occurring at the cell body level as well as occurring with the
projections these neural-like cells are developing. Significantly, this evidence indicates:
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1) our niche neural construct can produce a >85% viability increase compared to cells
seeded onto plastic. 2) These cells are more neural-like, showing a higher quality of
differentiation, cellular alignment, and changed morphology compared to cells seeded
onto plastic. 3) Successful neural differentiation of HADSCs can occur without the use of
the potentially cytotoxic or harmful chemicals utilized in neural induction.

5.3 In Vivo Efficacy
Stroke was successfully induced and a delivery mechanism for our construct was
validated. Large amounts of animal death are commonly associated with this procedure,
and our animal study was no exception. In future studies we anticipate this death rate to
lower based on surgeon and animal care staff familiarity with the procedure. As
previously mentioned, treatment delivery typically occurs at one day or seven days post
stroke. In future studies, employing a 7 day time point may provide the animals with
more recovery time, further improving the survival rate. The construct implantation was
ultimately more patient-specific than initially anticipated. Though the average infarcted
area determined by TCC staining was used as a general location for implantation, the
distinct textural differences between healthy and damaged brain tissue allowed for more
targeted treatment delivery.
Behavioral testing indicated the success of this treatment method from a
sensory/motor functional recovery perspective. Stroke controls did not show any
statistical improvement (P>0.1) over the 4 week period. Not only did the treatment group
show statistical improvement, but also this improvement was statistically different from
control rats as early as 2 weeks post stroke (P<0.5). It is also important to note that there
was no statistical difference in the week 0 mNSS scores between groups (P>0.1). Most
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significantly, the treatment group exhibited almost complete recovery by 4 weeks. It is
important to note that complete recovery indicates perfect completion of the mNSS
analysis; it is not a statement of complete return of all sensory or motor functions. More
behavioral tests would be necessary to understand exactly which types of functions have
completely recovered and which have not.
Histological examination of the stroke group revealed a visibly damaged area at
1 week post stroke. This tissue was extremely fragmented and overall does not stain
well – indicating significantly compromised tissue health. There is also significant
hemorrhage observed throughout this area. As dictated by the previously described
stroke pathology, this damaged tissue area eventually degraded resulting in a physical
void within the brain. This has been reported as early as 7 days in rat models.16 In our
study, this characteristic behavior was observed in the presented stroke controls by 4
weeks.
At 1 week post craniotomy, the treatment group showed significant cell presence
throughout  the  construct.  Masson’s  Trichrome  and  Movat’s  staining  confirmed very little
remodeling had occurred, as the majority of the construct was still comprised of
collagen. Some red blood cells remaining from stroke or craniotomy-related hemorrhage
were also observed. Alcian Blue staining showed initial tissue ingrowth occurring
between the folds of the construct; this tissue was almost exclusively GAGs.
Extensive and widespread tissue ingrowth occurred by 4 weeks. This tissue
appeared not well organized and was heavily populated by cells. The composition of this
newly formed matrix was not collagen, indicating a degree of scaffold degradation prior
to tissue ingrowth. Significantly, there was a large amount (relatable to fresh tissue) of
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GAG formation. Overall, this newly formed tissue greatly resembles granulation tissue,
the initial tissue type formed during the wound healing process.
The large population of cells necessitated an examination of neovascularization
within the construct area to determine if these cells were getting oxygen and general
nutrient supply. As figure 61 illustrates, vessels primarily 20µm in diameter were widely
spread throughout the newly formed matrix within the construct area. These vessels
showed distinct endothelial cell linings with a lumen filled with red blood cells, a strong
indication of the biocompatibility and integration of the construct by the host.
Further indications of integration and maintenance of the construct area as a
viable tissue result from in depth analysis of the cell types observed in this area.
Numerous cells throughout the construct stained positively for Nestin and Map-2,
indicating cells committing to neuron lineages. Interestingly, expression of both these
markers increases from 1 to 4 weeks. This could support the mechanism proposed by
Borlongan that stem cells act as bridges, providing a pathway for host neural cells to
migrate into damaged tissue areas. Contrastingly, no cells stain for GFAP confirming
that this area is not a host to reactive astrocytes and therefore no further analysis
relating to glial scarring was done. However, another measure to increase the validity of
this claim would be analysis of chondroitin sulfate.
Figure 64 shows an in depth analysis of the representative cell types populating
the scaffold area. Cell type A contains a larger cell body with a non-centered nucleus
and a visible nucleolus. These cells express Map-2 and contain Nissil bodies indicating
these cells are in fact a neuron. However, these cells were not observed in high
populations. Cell type B is very characteristic of a neuron. These cells contain Nissil
bodies, express Map-2 in a concentric ring around the cell body, and have a centrally
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located axon (in cross section). These cells were observed consistently throughout the
construct area and are overall one of the largest cell populations. Cell type F is the
stereotypical neuron. This neuron has numerous orientations including a darkly staining
area with or without a distinct nucleus/nucleolus. Additionally, the extensions of these
cells are visible in some orientations. These cells do stain positively for Map-2, but no
Nissil bodies are seen due to their orientation and dark staining.
Cell types C and D are both found in near proximity to the previously described
neurons. These cells appear to have no cytoplasm; they appear as one small (type C) or
large (type D) nucleus. Morphologically, these cells mimic accessory cell phenotypes.
Lack of Map-2 staining confirms these cells are not neurons, and lack of GFAP staining
indicates these cells are not astrocytes. They could be oligodendrocytes or another form
of accessory cell. Further analysis is required to confirm the identity of these cells.
The presence of cell type F clearly indicates leukocytes have been recruited to
the construct area. These cells are presumably macrophages, recruited to degrade the
scaffold in the initial phases of a wound healing response ultimately leading to tissue
remodeling and regeneration. IHC for rat macrophages confirmed a macrophage
presence (not shown). Importantly, no foreign body giant cells were observed anywhere
in the explanted tissue at either time point, a strong indicator of biocompatibility. This
also supports that the macrophages are present from remodeling mechanisms vs.
chronic inflammatory mechanisms.
The fate of the implanted HADSCs was examined through identification and
staining of human mitochondria. Figure 67 illustrates that populations of the HADSCs
have remained engrafted in the construct area. Though the exact amount of cells was
not quantified, there was significant engraftment and retention of these implanted cells to
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the damaged area. Most significantly, these cells still express Map-2, indicating these
cells have committed to a neuron lineage. To our knowledge this is the first data
supporting sustained neural differentiation of stem cells in a stroke animal model. Neural
induction has been previously confirmed in traumatic brain injury models; however, the
success refers to cells that have committed to a neural but non-neuron phenotype (i.e.
astrocytes, oligodendrocytes, and microglia). To our knowledge, this is the first data
supporting injected cell commitment to a neuron lineage over a 4 week period. A notable
amount of Map-2 expression co-localized with cell nuclei (but not co-localized with
human mitochondria staining) is observed throughout the construct area. This is another
indication that this research supports implanted cells recruiting host neural cells via
paracrine effects. However, as previously mentioned, HADSCs have maintained neural
protein expression and remained in the construct area indicating that mechanistically the
HADSCs’  functions  are  beyond  strictly  paracrine.
Histological analysis of the interface served as a final assessment of construct
integration and biocompatibility. Overall, there were no indications of fibrous
encapsulation. There is no gap between the host tissue and construct tissue. There is a
strong presence including cells that are oriented orthogonal to the interface. The area is
contains extensive cell populations including neurons. Cells on both sides of the
interface express Nestin and Map-2 indicating a strong neuron and neural cell presence
in the area. No GFAP expression was observed within the construct and the quantities of
GFAP positive cells on the host side of the interface was consistent with the numbers
found in healthy brain tissue. More in depth examination of the host-side of the interface
reveals no glial encapsulation, indicating the scaffold is not contributing to or promoting
anti-regenerative astrocyte activity. Lastly, this are is well vascularized (see figure 68).
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CHAPTER 6: CONCLUSIONS

A novel neural scaffold was successfully created and characterized using a
tissue engineering approach. Specifically this scaffold showed an intact matrix, almost
no DNA remnants, no cellular remnants, and retained basement membrane proteins.
In vitro cell seeding studies confirmed the ability of this scaffold to support and
maintain the viability and neural protein marker expression of both NIM-induced and
non-induced cell types up to 5 days. Most significantly, the scaffold does promote the
unaided differentiation of HDSCs into cells of great neural likeness and maintains these
cells, indicating the scaffold is in fact a stem cell niche.
Niche neural constructs were successfully implanted into stroke-afflicted rats
resulting in significant sensory/motor functional recovery as well as the continual support
of life and neural likeness of HADSCs as well as host neural cells. After 4 weeks,
implanted HADCSs remained in the construct area and appeared to be committed to a
neuron lineage. To our knowledge, this is the first evidence suggesting significant
retention of implanted stem cells to damaged stroke areas as well as the first evidence
validating neural induction in animal stroke models. There was significant evidence
suggesting this construct was integrating with host tissue. There was no evidence of
fibrous encapsulation at the interface, which was vascularized and the host of numerous
neurons among other cell types. Additionally, the construct had begun to degrade to
make way for a newly formed vascularized neural matrix. Overall, these results support
the future use of this niche neural construct for the next generation of stroke treatments.
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CHAPTER 7: RECOMMENDATIONS
Though the niche potential of this scaffold was confirmed to 5 days, longer
studies are needed since any clinical application would necessitate use past 5 days.
Also, HADSCs have been proven to revert from a neural lineage after the neural
induction process. Longer studies are required to ensure the non-induced group does
not show this same behavior as the viability of the cells wanes. Additionally, I would
suggest combinations of NIM and MesenPRO media be utilized in the in vitro
conditioning of the niche neural constructs. The evidence presented in this work shows
significant evidence suggesting NIM induction yields faster differentiation while the noninduced cells exhibit maintained differentiation and viability percentages nearing clinical
relevance. A combination of these (ex. 1 day exposure to NIM followed by MesenPRO)
may lead to more efficient niche neural construct preparation.
The goal of this research was to establish preliminary efficacy of this niche neural
construct in stroke treatment applications. More in depth analyses are required to further
confirm sensory/motor recovery and understand the regeneration observed in the
construct region. More involved behavioral tests such as the adhesive removal test, food
grabbing test, and NSS scoring system could be employed to achieve a better and more
thorough representation of damage. Additionally, the researcher performing these
analyses must be blind to the condition of the rats. Another important consideration in
the framework of the study is to include more control groups (scaffold only, and sham
craniotomy) and overall larger animal numbers in order to achieve a higher degree of
statistical relevance. Since there is significant evidence suggesting new matrix
formation, analysis of neurotrophic factors and other neural matrix proteins would
confirm that this newly formed matrix is actually brain matrix. A much longer study would
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also allow for the establishment of a neural regeneration timeline. For example, a twoweek timeline is appropriate for analysis of skin regeneration; due to very minimal
success in this area neural matrix regeneration has no generally accepted timeline. The
vast abundance of neurons in the regenerated area begs the question: are these
functional neurons. This research preliminarily suggests that are, but examination of
more neuron-specific proteins such as sox2 and NeuN as well as an electrical
examination or neurotransmitter release would prove very useful.
To further advance this research towards a translational application, I would
suggest at least one study be completed where the niche neural constructs are prepared
using autologous cells as opposed to human adipose derived stem cells. I would also
suggest that minimally invasive methods of delivery be investigated, as minimally
invasive procedures would be safer and overall more appealing to patient populations.
Additionally, turning this scaffold into a manufacturable product will require further
research, specifically investigating a shorter time line of decellularization. Initial efforts I
would suggest include changing variables such as agitation speed as well as the shapes
of the containers employed during decellularization.
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APPENDIX A: Extra Figures

Extra Figure 1: Map-2 staining overlayed with DAPI nuclear stain to demonstrate staining is in fact co-localized with
cell nuclei.

Extra figure 1 clearly illustrates that the Map-2 expression previously shown is in
fact co-localized with a cell nucleus. These images were provided as an additional
measure to ensure the green fluorescence observed is in fact positive staining. This
further confirms our previous conclusions that these cells are in fact expressing and
maintaining the expression of the neuron marker Map-2.
Extra figures 2 and 3 were provided to enable the viewer to directly compare the
neural marker expression between groups. At lower magnification, it is clear the
previously represented expression is representative. Extra figure 3 clearly portrays the
developing extensions and projections of the cells and provides clearer evidence that the
cells have maintained marker expression.
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Extra Figure 2: Comparative matrix of in vitro studies at lower magnification to demonstrate representativeness of
staining.

Both figures 2 and 3 support the previously reported conclusions that we have
replicated the neural induction process for human adipose derived stem cells seedded
onto plastic. Up to the 5 day timepoint, these cells are morphologically changing and
expressing key neural proteins. However,

by day 5 a lack of viable cell presence

hinders analysis of protein marker expression, although extra figure 2 seems to indicate
a degree of expression was still maintained.
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Extra Figure 3: Comparative matrix of in vitro studies at higher magnification. Morphological changes as well as the
extent of co-localized staining is more readily apparent.

Extra figure 4 illustrates the extreme morphological changes observed within the
niche neural constructs. Cells appear to consist of one large cell body with extensive
projections. These projections extend up to 450µm in some cases. The arrows point to
such projections. The box at the right, outlines an entire cell, which morphological
analysis dictates is phenotypically a neuron. This analysis further bolsters our claims that
this niche neural construct can produce and maintain neurons.
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Extra Figure 4: Live/Dead staining of niche neural constructs (representative of study 6, cells seeded onto scaffolds
with no induction step where the media was replaced daily). The cells have formed large cell bodies with projections
that elongate as much as 450µm.

Extra figures 5 and 6 provide further in depth analysis of the fate of the implanted
HADSCs. Consistent with the previously presented IHC staining, there is no GFAP
expression within the construct area. More significantly, we have confirmed the
implanted HADSCs have not committed to an astrocyte lineage. As previously described

Extra Figure 5: Human mitochondria - GFAP Double Staining. Results are consistent with
the IHC results presented in figure 62.Green indicates GFAP. Red indicates human
mitochondria. Blue indicates DAPI nuclear staining.
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a large portion of these implanted HADSCs express Map-2, indicative of commitment to
a neuron lineage. To further confirm this and to very preliminarily assess the functionality
of these neurons, expression of Synapsin I, a key protein involved in synaptic
connections, was analyzed. As seen below, a significant amount of Synapsin I
expression is observed, further confirming a neuron presence within the construct area
indicating a degree of functionality of these neurons.

Extra Figure 6: Human mitochondria – Synapsin I Double Staining. Explants were stained
for Synapsin I, a key protein of synaptic connections, as a preliminary assessment of the
functionality of the neurons observed within the construct area. Green indicates Synapsin
I. Red indicates human mitochondria. Blue indicates DAPI nuclear staining.

Staining for myelin was another measure employed as a preliminary functional
assessment of the neurons within the construct area. The patchy nature and overall
faintness of the staining observed in the construct area does not permit any myelinbased conclusions at this time.
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Extra Figure 7: Luxol Fast Blue Staining for Myelin. Explants exhibit blue staining; however, the inconsistent and faint
nature of staining could indicate a false positive or background staining. Overall, this preliminary myelin assessment is
inconclusive.
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